News BMS files legal challenge to HHS' 340B rebate decision Bristol-Myers Squibb has become the latest pharma in the US to file a legal challenge to a block on a 340B drug rebate model opposed by HRSA.
News Pfizer's COVID boom goes on, as it eyes $22bn in Paxlovid sa... Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirna
News 23andMe fined £2.31m over UK users' genetic data breach Genetic testing company 23andMe is facing a hefty fine from the UK's data protection watchdog for failing to protect its customers' data.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face